The NAFLD surrogate marker, ALT, was significantly decreased in the ipragliflozin group (from 33.4 ± 25.1 IU/L to 25.6 ± 16.9 IU/L and from 31.1 ± 13.5 IU/L to 26.5 ± 11.8 IU/L in the ipragliflozin add-on and metformin + pioglitazone maintenance groups, respectively; p < 0.001) Similarly, γ-GT was significantly decreased in the ipragliflozin group (from 40.9 ± 47.8 IU/L to 29.7 ± 24.6 IU/L and from 31.8 ± 15.6 IU/L to 29.9 ± 13.8 IU/L in the ipragliflozin add-on and metformin + pioglitazone maintenance groups, respectively; p < 0.001) (Table 2). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.